oral CD38 inhibitor

in vivo efficacy in a murine model of cardiac I/R

from the previously disclosed inhibitor CD38i

J. Med. Chem.

Mitobridge (an Astellas Company), Cambridge, MA

MK-0159 Chemical Structure oral CD38 inhibitor - Mitobridge (an Astellas Company), Cambridge, MA

Context. MK-0159 (Mitobridge) is an oral CD38 inhibitor being developed for cardiovascular diseases. Due to its NADP+ depleting activity, which has implications for calcium homeostasis, the cell surface marker…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: